Scott Rocklage of 5AM Ventures is helping to lead the way toward a cure for the genetic disorder, Myotonic Dystrophy Type I. This horrible disease is the root cause of Muscular Dystrophy in adults. Rocklage, along with Sanofi Ventures, Novartis Venture Fund, and Kleiner Perkings are helping Expansion Therapeutics secure Series A financing. The group has already raised over $55 million toward finding a cure for this disease.
DM1, as the disease is called, occurs when certain RNAs inside of cells rise to toxic levels which cause the heart, muscles, and central nervous systems in the body to break down. This disease is hereditary and has been known to infect entire families, becoming more debilitating with each generation. There is no cure or even an effective treatment for this disease.
There has recently been a breakthrough in the treatment of DM1, which was discovered by Dr. Matthew Disney, and it can now be treating with small molecule medications. The only problem is the laborious process of getting these treatments to market. That is where Scott Rocklage and his team come into play, raising millions of dollars to help get the treatment into the hands of those who need it. Read more: Scott Rocklage | Crunchbase and Scott Rocklage | Bloomberg
Dr. Scott Rocklage is a managing partner of venture capital firm, 5AM Ventures. The company secures financing for life science and pharmaceutical companies. Dr. Rocklage has been with 5AM Ventures since 2003, after nearly 20 years in healthcare management. He received a Bachelor’s degree in Chemistry from the University of California-Berkeley and his Ph.D. from MIT, where he was a research assistant for Nobel Peace Prize winner, Dr. Richard Schrock.
Rocklage is an accomplished inventor with over 30 U.S. patents awarded to his inventions and has led three drugs through the FDA approval process: Teslascan, Omniscan, and Cubicin. He has served on the board of numerous pharmaceutical companies including Relypsa, Novira, and Achaogen.
He previously worked as the CEO and Chairman of Cubist Pharmaceuticals. He is currently the Chairman of the Board of Directors for Cidara, Kinestral and Rennovia. Dr. Rocklage’s office is located in the Boston, MA area where he lives.
Learn more about Scott Rocklage: